ABHIXAmerican Century High-Yield Bond Fund Investor Class
The schedule
- Wed28Oct
(Driven by CVNA) The Q3 2026 earnings release is a significant event that will provide investors with insight into the company's financial performance for the quarter. This event is expected to have a high impact on the stock price, as it will include guidance for the upcoming quarter. The stock is projected to rise to a target of $80.45, but there is a fallback level at $66 in case of a negative outcome. The probability of a bullish outcome is 50%, indicating a balanced expectation for the event.
- Thu14Jan
(Driven by STX) Key technology showcase focusing on HAMR adoption rates and hyperscaler deployment roadmaps.
- Tue9Feb
(Driven by CVNA) The Q4 2026 earnings release is a major event that will provide investors with insight into the company's financial performance for the quarter. This event is expected to have a high impact on the stock price, as it will include guidance for the upcoming quarter. The stock is projected to rise to a target of $90.37, but there is a fallback level at $64 in case of a negative outcome. The probability of a bullish outcome is 50%, indicating a balanced expectation for the event.
- Wed10Mar
(Driven by STX) Market evaluation of broader hyperscaler capex trends and potential normalization of AI infrastructure spending.
- Wed31Mar
(Driven by VST) Stephen Mandel's 13F filing is an important event that may indicate a shift in institutional holdings, potentially signaling a strategic investment in renewable energy infrastructure. This filing could influence market perception of the company's long-term prospects and its position in the energy sector. The filing is expected to provide insight into the types of assets and projects that are attracting significant institutional interest.
- Wed5May
(Driven by CVNA)
- Thu17Jun
(Driven by CVNA) This event is related to a potential announcement regarding a single factor that is currently holding back the company's performance. The news could provide clarity on the issue and its impact on the business. The stock is expected to rise to a target of $101.39, but there is a fallback level at $68 in case of a negative outcome. The probability of a bullish outcome is 40%, indicating a more cautious outlook for this event.
- Wed28Jul
(Driven by CVNA) The Q2 2027 earnings release is a significant event that will provide investors with insight into the company's financial performance for the quarter. This event is expected to have a high impact on the stock price, as it will include guidance for the upcoming quarter. The stock is projected to rise to a target of $102.92, but there is a fallback level at $62 in case of a negative outcome. The probability of a bullish outcome is 50%, indicating a balanced expectation for the event.
Past
- Fri7Aug
Actual outcome: Bull
The stock closed at $5.17, reaching the bull target of $5.19, indicating a positive price reaction. The earnings release showed progress on the capital-light strategy, with improved guidance on revenue stabilization and cash flow generation, reinforcing investor confidence in the long-term direction of the company.
The stock closed at $5.17, reaching the bull target of $5.19, indicating a positive price reaction. The earnings release showed progress on the capital-light strategy, with improved guidance on revenue stabilization and cash flow generation, reinforcing investor confidence in the long-term direction of the company.
- Sat20Jun
Actual outcome: Bull · $5.17 at outcome
Despite the advancement of US PBM reform and drug pricing legislation targeting CVS Health's Caremark division, ABHIX remained resilient. The fund's diversified high-yield credit portfolio insulated it from the sector-specific legislative risks, allowing the price to hold steady and exceed the bull target.
Despite the advancement of US PBM reform and drug pricing legislation targeting CVS Health's Caremark division, ABHIX remained resilient. The fund's diversified high-yield credit portfolio insulated it from the sector-specific legislative risks, allowing the price to hold steady and exceed the bull target.
- Wed17Jun
Actual outcome: Bull · $5.17 at outcome
The June FOMC meeting held interest rates steady while signaling a more dovish trajectory for future rate cuts. This favorable macroeconomic outlook eased borrowing cost concerns for capital-intensive REITs like SBAC, supporting the fund's valuation and allowing it to reach its bull target.
The June FOMC meeting held interest rates steady while signaling a more dovish trajectory for future rate cuts. This favorable macroeconomic outlook eased borrowing cost concerns for capital-intensive REITs like SBAC, supporting the fund's valuation and allowing it to reach its bull target.
- Wed20May
Actual outcome: Bull · $5.17 at outcome
Carvana delivered a strong Q1 2026 earnings print, highlighted by stabilizing gross profit per unit (GPU) and controlled reconditioning costs. This confirmation of sustainable profitability and continued growth satisfied market expectations, driving the positive outcome and allowing the price to reach the bull target.
Carvana delivered a strong Q1 2026 earnings print, highlighted by stabilizing gross profit per unit (GPU) and controlled reconditioning costs. This confirmation of sustainable profitability and continued growth satisfied market expectations, driving the positive outcome and allowing the price to reach the bull target.
- Wed15Apr
Actual outcome: Bull · $5.18 at outcome
The final CMS 2027 rate notice provided a slight upward revision to reimbursement levels compared to the initial flat-rate proposal, alleviating fears of severe margin contraction for CVS's Aetna business. This improved regulatory outlook signaled a less punitive environment for Medicare Advantage providers, supporting the bull case as investors moved past the worst-case
The final CMS 2027 rate notice provided a slight upward revision to reimbursement levels compared to the initial flat-rate proposal, alleviating fears of severe margin contraction for CVS's Aetna business. This improved regulatory outlook signaled a less punitive environment for Medicare Advantage providers, supporting the bull case as investors moved past the worst-case
